

## Review Form 1.6

|                          |  |
|--------------------------|--|
| Journal Name:            | <a href="#">Journal of Pharmaceutical Research International</a> |
| Manuscript Number:       | Ms_JPRI_79488  |
| Title of the Manuscript: | Pathophysiology Of Complication in Diabetes Mellitus             |
| Type of the Article      |  |

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

**Review Form 1.6**

**PART 1: Review Comments**

|  | Reviewer's comment  | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|--|---|---|
| <p><b>Compulsory</b> REVISION comments</p> | <p>In Abstract I would recommend to replace “sugar” with “glycemic”, also I think that should be reformulated that “A patient suffers from type 2 diabetes if the cells don't respond to insulin.”- I would comment that in type 2 diabetes it is a battle of insulin resistance and/or hyperinsulinism, in varying degrees. For the keywords I think that it would be more appropriate to use :complications, diabetes mellitus, pathophysiology In introduction :” Diabetic individuals usually have compromised exocrine pancreas function” it is wrong, because in diabetes mellitus it is about the endocrine pancreas function. Also you should replace “sugar” with glycemic.<br/>                     This : “There are three distinct symptoms of type 1 diabetes: Polyuria, Polydipsia, and Polyphagia” it is wrong because not only In type 1 diabetes we find these symptoms but also in type 2 and the symptoms more frequently are :<br/>                     polyuria, polydipsia, weight loss, polyphagia, and in the type 1 diabetes, the marked symptom is the rapid weight loss in a short time of a large number of kilograms.<br/>                     “may result in large amount of ketone bodies in the body such as acetoacetate, acetone and -hydroxy butyrate, which can lead to coma in patients suffering from type 1 diabetes”- these can lead to inaugural type 1 diabetes.<br/>                     “ Dehydration and a loss of consciousness in an older person are typical symptoms of the condition, which is also characterised by hyperglycemia but no signs of ketoacidosis”= This phrase refers to hyperosmolar coma of type 2 diabetes and not type 1 diabetes.<br/>                     ” . The most frequent kind of diabetes is type 1 Type 2 diabetes which affects about 95% of diabetics.”—the most frequent is type 2 diabetes!</p> <p>A SUMMARY OF DIABETES COMPLICATIONS<sup>4</sup>—here I would like to see a more compact classification like: microvascular complications are ....macrovascular complications are,, and for these another exemple.</p> <p>The most recent classification of retinopathy I think that is needed when you speak about retinopathy.</p> <p>Peripheral arterial disease (PAD)- for staging we are we are blocked by an overlapping neuropathy that can mask the early stages of this disease, you can debat these here. Also when we speak about diabetes and the complications of theses condition, we cannot say thata the people have only one complication, in the most of time they have an overlap of complications that clinicians cannot detect.</p> |   |
| <p><b>Minor</b> REVISION comments</p>      |   |   |
| <p><b>Optional/General</b> comments</p>    |   |   |

Review Form 1.6

**PART 2:**

|   | <b>Reviewer's comment</b>  | <b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i> |
|---|--|---|
| <b>Are there ethical issues in this manuscript?</b> | <i>(If yes, Kindly please write down the ethical issues here in details)</i> |   |

**Reviewer Details:**

|                                  |   |
|----------------------------------|---|
| Name:                            | <b>Miculescu Alexandra Maria</b>                            |
| Department, University & Country | <b>University of Medicine and Pharmacy Craiova, Romania</b> |